Changrui Biotech participated in the signing ceremony of Chengdu Tianfu International Biocity with a total investment of more than 11 billion yuan - 2022 circle building strong chain project

Category:

Release time:2023-02-02

On June 10, 2022, Chengdu Tianfu International Biocity held a centralized signing ceremony for the "2022 Building a Circle and Strong Chain" project, and 14 projects were signed at the event site, with a total investment of more than 11 billion yuan.

Major funds such as

Waige Guosheng Fund and Essence Guosheng Microchip Fund will further promote innovative enterprises to improve their R&D pipelines, provide all-round services such as optimizing the company's management structure and docking medical market resources, promote the gathering of more advantageous resources, and strive to incubate and cultivate a listed company of large-molecule innovative drugs within three to five years.

As one of the major signed projects, Changrui Biotechnology (Chengdu) Co., Ltd. settled in Tianfu International Biocity in 2021, and cooperated with the top 100 domestic pharmaceutical industry enterprises to land a one-stop service platform for carrier drug development and macromolecular biologic CDMO in Biocity, creating a full-chain R&D and industrialization technology service platform covering CRO, CMO, CDMO.

The 21st century is an era of rapid development of biotechnology, and many new biological drugs with precise targets, clear effects, positive efficacy and good safety have been born in the field of medicine, allowing mankind to make great progress in the fight to treat and prevent diseases. As the research and development of biological drugs has become a hot spot in pharmaceutical research and development, a large amount of funds and resources have been invested in it, the research and development track has become crowded, the development competition has become fierce, and the development cost and speed of new drugs have become the key to stand out in this biological drug research and development war.

Changrui Biotech has 6 major technology platforms: carrier drug construction screening and incubation platform, viral drug industrialization development platform, animal cell drug industrialization development platform, recombinant protein drug industrialization development platform, detection analysis and quality research platform, drug registration management platform, and a perfect quality management system in line with Sino-US double report, which can rely on the international biomedical industry ecosystem of Biocity facing the world, serving the world, and integrating into the world. Transformational enterprises provide full biologic drug development services from structure discovery to registered sample preparation, accelerating the development of drugs that are urgently needed in clinical practice.

key words: Changrui Biotech participated in the signing ceremony of Chengdu Tianfu International Biocity with a total investment of more than 11 billion yuan - 2022 circle building strong chain project

relevant